The current guidelines from the American Association for the Study of Liver Diseases (AASLD) recommend that individuals with CHB receive regular monitoring every six months with abdominal ultrasound and blood tests for liver function, HBV load, and alpha-fetoprotein (AFP) levels [3,4,5,6]. This evidence concerns the gene AFP and liver disorder.